NCT06259669View on ClinicalTrials.gov

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

RecruitingOBSERVATIONAL
Enrollment

958

Participants

Timeline

Start Date

September 13, 2023

Primary Completion Date

August 1, 2032

Study Completion Date

August 1, 2033

Conditions
Pregnancy RelatedAtopic Dermatitis
Interventions
DRUG

Ruxolitinib Cream

Ruxolitinib Cream

Trial Locations (1)

27560

RECRUITING

Syneos Health (remote site), Morrisville

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT06259669 - Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population | Biotech Hunter | Biotech Hunter